| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| NVS | Novartis AG | $85.13 | $197.65B | Downtrend |
Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT
http://www.zacks.com/stock/news/330069/biotech-stocks-earnings-lineup-for-oct-24-vrtx-alxn-srpt?cid=CS-ZC-FT-330069
Oct 23, 2018 - Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.
0
Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates
http://www.zacks.com/stock/news/329878/novartis-nvs-q3-earnings-in-line-revenues-beat-estimates?cid=CS-ZC-FT-329878
Oct 22, 2018 - Novartis (NVS) beats sales estimates in Q3, driven by Cosentyx and Entresto, while earnings came in line. The company plans to acquire Endocyte to broaden its oncology pipeline.
0
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?
http://www.zacks.com/stock/news/329755/biib-alks-q3-earnings-due-on-oct-23-whats-in-store?cid=CS-ZC-FT-329755
Oct 22, 2018 - We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.
0
Novartis Bolts On New Radioligand Therapy For Treating Prostate Cancer
https://seekingalpha.com/article/4213053-novartis-bolts-new-radioligand-therapy-treating-prostate-cancer?source=feed_sector_healthcare
Oct 22, 2018 - Novartis paid $2.1 billion to acquire Endocyte for its radioligand therapy candidate PSMA-617.The acquisition of Endocyte was a smart strategic move because it builds upon a prior acquisition that als
0
OptimizeRx Acquires CareSpeak Communications For Patient Health Messaging
https://seekingalpha.com/article/4212883-optimizerx-acquires-carespeak-communications-patient-health-messaging?source=feed_all_articles
Oct 19, 2018 - OptimizeRx has acquired CareSpeak Communications for up to $8.5 million in total consideration.CareSpeak has developed a mobile-first patient communication system.OPRX has achieved rapid growth in rec
0
Biotech Stocks Bloodied But Can Now Drive M&A
https://seekingalpha.com/article/4212760-biotech-stocks-bloodied-can-now-drive-m?source=feed_tag_etf_portfolio_strategy
Oct 19, 2018 - The biotech stocks plunge along with the broader market, as the smallcap and midcap biotech stocks retreat -17%.The larger cap biotechs and pharma are performing relatively much better.The performance
0
Novartis' (NVS) CEO Vas Narasimhan on Q3 2018 Results - Earnings Call Transcript
https://seekingalpha.com/article/4212603-novartis-nvs-ceo-vas-narasimhan-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare
Oct 18, 2018 - Novartis AG (NYSE:NVS) Q3 2018 Earnings Conference Call October 18, 2018 8:00 AM ET Executives Samir Shah – Global Head-Investor Relations Vas Narasimhan – Chief Executive Officer Harry Kirsch – Chief
0
Novartis to Buy Biopharmaceutical Company Endocyte for $2.1 Billion
http://www.gurufocus.com/news/755502/novartis-to-buy-biopharmaceutical-company-endocyte-for-21-billion
Oct 18, 2018 - Novartis to Buy Biopharmaceutical Company Endocyte for $2.1 Billion, Stocks: NVS,ECYT, release date:Oct 18, 2018
0
Novartis AG 2018 Q3 - Results - Earnings Call Slides
https://seekingalpha.com/article/4212432-novartis-ag-2018-q3-results-earnings-call-slides?source=feed_sector_healthcare
Oct 18, 2018 - The following slide deck was published by Novartis AG in conjunction with their 2018 Q3 earnings call.
0
Novartis Reports Positive Long-Term Data From Cosentyx Trials
http://www.zacks.com/stock/news/328979/novartis-reports-positive-long-term-data-from-cosentyx-trials?cid=CS-ZC-FT-328979
Oct 18, 2018 - Novartis (NVS) announces encouraging five-year data from late-stage studies on Cosentyx for psoriatic arthritis and ankylosing spondylitis indications.
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| MRK | Merck & Company, Inc. | NYSE | $70.42 | $187.28B |
| ABBV | AbbVie Inc. | NYSE | $95.37 | $144.42B |
| PFE | Pfizer, Inc. | NYSE | $43.01 | $252.13B |
| ABT | Abbott Laboratories | NYSE | $67.67 | $118.71B |
| NVO | Novo Nordisk A/S | NYSE | $47.64 | $114.84B |